Catheter Ablation Versus Radio-Ablation for Ventricular Tachycardia: a Randomized Controlled Trial

This study compares two arms - the current standard of care catheter ablation for Ventricular Tachycardia compared to stereotactic radiotherapy to non-invasively ablate ventricular tachycardia using a novel non-invasive ECG based body surface mapping technology. This allows investigators to identify ventricular tachycardia circuits to target for subsequent radio ablation. To summarize, the current standard of care invasive catheter ablation to the non-invasive radio ablation.

Currently patients suffering Ventricular Tachycardia (VT) are offered drugs, such as Amiodarone, Implantable cardioverter defibrillatorf (ICD) implant and catheter ablation. Although effective drugs have side effects, ICD shocks are painful and catheter ablation is arduous for patients at high risk of complications. Catheter ablation is currently the gold standard treatment for recurrent VT despite anti-arrhythmic drugs (AADs).

Catheter ablation (CA) was initially developed in the 1980s following the successful treatment of VT by surgical resection of myocardial scarring in structural heart disease. After thorough clinical evaluation and medical stabilization, imaging is performed to identify culprit areas for ablation and to stratify risk of intervention. Pre procedural imaging in patients with ICDs in situ involves Echocardiography, Computerized Tomography (CT) scanning and Positron Emission Tomography (PET) imaging in order to assess cardiac function, ischemia, inflammation and scarring. If necessary mechanical circulatory support, Left Ventricular Assist Devices (LVAD) and/ or Extra Corporeal Membrane Oxygenation (ECMO) can be used to sustain cardiac output during VT induction and mapping.

Radiofrequency (RF) energy delivered via catheter to the arrhythmogenic target results in local resistive heating and is performed under sedation or anesthesia using multiple catheters placed in the heart while the patient is anticoagulated. Conventional approaches involve advancing multiple catheters via Femoral veins and/or arteries under a combination of fluoroscopic, ultrasound and electroanatomic guidance. Ablation targets include an arrhythmogenic focus or the critical isthmus of the VT circuit and/ or substrate identified on preprocedural imaging or low voltage areas, "scar", identified during endocardial mapping. CA procedures for VT are often long, averaging 5 hours duration reported in clinical trials, with prolonged procedures being associated with adverse outcomes and 30 day complication rates, including death, of 7- 13%.

Vulnerable patients requiring circulatory support or at high risk of recurrence and death following catheter ablation can be identified pre-operatively. Of all patients undergoing CA for VT, more than a third are "high risk" with a one year risk of death of \>20%. Patients older than 65 with prior catheter ablation and recurrent VT with impaired left ventricular ejection fraction ≤35% have 90 day VT recurrence rates of 30% and mortality of 20%.

Patients with comorbidities such as Diabetes or COPD and those presenting in VT storm are also at high risk of hemodynamic compromise and death following Catheter Ablation. Without prophylactic LVAD placement, patients at high risk of haemodynamic instability (PAINESD score ≥ 15) suffer 30% death at thirty days with 41% VT recurrence post CA. It is these "high risk" patients that we believe will benefit from a non-invasive RA approach.

Patients undergoing a non-invasive Radio-Ablation (RA) procedure for VT similarly require medical stabilization and multimodal imaging prior to treatment. Instead of an invasive catheter-based electrophysiology study (EPS) and ablation, a non-invasive EPS (NIPS) is performed under light sedation using ECGi mapping. This short procedure, averaging 40 minutes, requiring only the placement of an IV cannula for light sedation, uses the ICD to stimulate VT which is mapped in real time using the CardioInsight ECGi mapping system.

The multimodal imaging data is digitally fused and then combined with the ECGi data to identify the VT circuit(s) and to target the arrhythmogenic tissue for radio-ablation. This analogue process is performed off- line by a committee of Cardiac Imaging and EP Cardiologists and a Radiation Oncologist. Once the target(s) are identified, the treatment plan is sent to Medical Physics for alignment on a 4D planning CT performed with breath holding in the radiotherapy suite. Final treatment targets are reviewed by the local treating team and discussed with our collaborators in St Louis. Thereafter the patient is booked for a 15 minute out-patient radiotherapy treatment performed on a standard linear accelerator.

Photon radiotherapy, as commonly used in cancer therapeutics across Canada, is guided using a cone beam onto the cardiac target(s). A single fraction of 25 Gy is delivered painlessly over 15 minutes. Although minor side effects have been reported, serious adverse events are rare and no ICD related issues have been described. No deleterious effects on cardiac function (LVEF) have been observed although approximately (5/65? TBC) patients have required a two week course of oral glucocorticoid therapy for symptomatic inflammation such as pericarditis or pneumonitis post RA25. All patients are treated with Rivaroxaban 20 mg po as prophylaxis against thromboembolism for thirty days post RA.

Radioablation is a novel procedure and long-term outcomes remain unknown. Reduction in VT is reported to be 85-92% up to 6 months post RA and in the ENCORE -VT study 17 of 19 patients were free from ICD shocks at 6 months. In the only prospective study of RA for VT, patients reported an improvement in quality of life in 5 of 9 domains remaining unchanged in 4. Long term safety data continue to be collected but cardiac irradiation \<40 Gy has been historically associated with an approximate 1% excess mortality over years to decades in those receiving treatment for breast or lung cancer. This is in the context of a total mortality of 28% over 24 months of follow up in those undergoing CA for recurrent VT in Canada.

Eligibility Criteria:
Inclusion Criteria:

1. Patient aged ≥55 years of age
2. Cardiomyopathy (Left ventricular ejection fraction ≤ 35% and ICD in situ) AND
3. Recurrent VT events despite previous CA OR
4. VT events requiring intervention and PAINESD score ≥ 15

Exclusion Criteria:

1. Patients with NYHA Class IV heart failure \&/ or with LVAD in situ
2. Patients not expected to live for more than one year for any reason
3. Patients who have previously received thoracic radiotherapy
4. Patients who are enrolled in another randomized clinical trial
5. Patients who are unable or unwilling to provide informed consent
6. Patients aged ≤54 years of age
7. Pregnancy (all women of child bearing age and potential will have a negative β-HCG test before enrollment)
8. Breastfeeding
9. Women of childbearing age who refuse to use a highly effective and medically acceptable form of contraception (IUD, sterilization, birth control implant or birth control pill) throughout the study.